Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
The observations are procedural in nature and will be responded to within the stipulated time
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
The product will be launched in Q1FY26
Subscribe To Our Newsletter & Stay Updated
